RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes
dc.contributor.author | Armstrong, Allison P. | en_US |
dc.contributor.author | Miller, Robert E. | en_US |
dc.contributor.author | Jones, Jon C. | en_US |
dc.contributor.author | Zhang, Jian | en_US |
dc.contributor.author | Keller, Evan T. | en_US |
dc.contributor.author | Dougall, William C. | en_US |
dc.date.accessioned | 2007-12-04T18:27:41Z | |
dc.date.available | 2009-01-07T20:01:16Z | en_US |
dc.date.issued | 2008-01-01 | en_US |
dc.identifier.citation | Armstrong, Allison P.; Miller, Robert E.; Jones, Jon C.; Zhang, Jian; Keller, Evan T.; Dougall, William C. (2008). "RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes." The Prostate 68(1): 92-104. <http://hdl.handle.net/2027.42/57344> | en_US |
dc.identifier.issn | 0270-4137 | en_US |
dc.identifier.issn | 1097-0045 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/57344 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18008334&dopt=citation | en_US |
dc.description.abstract | BACKGROUND Metastases to bone are a frequent complication of human prostate cancer and result in the development of osteoblastic lesions that include an underlying osteoclastic component. Previous studies in rodent models of breast and prostate cancer have established that receptor activator of NF-ΚB ligand (RANKL) inhibition decreases bone lesion development and tumor growth in bone. RANK is essential for osteoclast differentiation, activation, and survival via its expression on osteoclasts and their precursors. RANK expression has also been observed in some tumor cell types such as breast and colon, suggesting that RANKL may play a direct role on tumor cells. METHODS Male CB17 severe combined immunodeficient (SCID) mice were injected with PC3 cells intratibially and treated with either PBS or human osteprotegerin (OPG)-Fc, a RANKL antagonist. The formation of osteolytic lesions was analyzed by X-ray, and local and systemic levels of RANKL and OPG were analyzed. RANK mRNA and protein expression were assessed on multiple prostate cancer cell lines, and events downstream of RANK activation were studied in PC3 cells in vitro. RESULTS OPG-Fc treatment of PC3 tumor-bearing mice decreased lesion formation and tumor burden. Systemic and local levels of RANKL expression were increased in PC3 tumor bearing mice. PC3 cells responded to RANKL by activating multiple signaling pathways which resulted in significant changes in expression of genes involved in osteolysis and migration. RANK activation via RANKL resulted in increased invasion of PC3 cells through a collagen matrix. CONCLUSION These data demonstrate that host stromal RANKL is induced systemically and locally as a result of PC3 prostate tumor growth within the skeleton. RANK is expressed on prostate cancer cells and promotes invasion in a RANKL-dependent manner. Prostate 68: 92–104, 2008. © 2007 Wiley-Liss, Inc. | en_US |
dc.format.extent | 439317 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Department of Urology, School of Medicine, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | University of Michigan, Department of Urology, School of Medicine, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Departments of Hematology/Oncology Research, Amgen Inc., Seattle, Washington | en_US |
dc.contributor.affiliationother | Departments of Hematology/Oncology Research, Amgen Inc., Seattle, Washington | en_US |
dc.contributor.affiliationother | Departments of Hematology/Oncology Research, Amgen Inc., Seattle, Washington | en_US |
dc.contributor.affiliationother | Departments of Hematology/Oncology Research, Amgen Inc., Seattle, Washington ; Departments of Hematology/Oncology Research, Amgen Washington, 1201 Amgen Court West, Seattle, WA 98119. | en_US |
dc.identifier.pmid | 18008334 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/57344/1/20678_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/pros.20678 | en_US |
dc.identifier.source | The Prostate | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.